France
France-HiT
France-HiT
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Health systems in transition <strong>France</strong> 163<br />
Economic evaluation is the newest cost-containment tool. Until recently,<br />
coverage and pricing decisions were made following HTA evaluations that<br />
were principally based upon clinical efficacy, not on cost–effectiveness or<br />
value to broader society. However, since October 2013, economic evaluation<br />
has been required for drugs meeting two conditions: having been evaluated as<br />
innovative (ASMR level 1, 2 or 3) and likely to have a significant impact on<br />
SHI expenditure (annual sales of €20 million or more in the first two years).<br />
The CEESP undertakes its assessment simultaneously with the Transparency<br />
Commission’s evaluation of the SMR and ASMR of the drug (see section 2.8.4)<br />
to avoid undue delay before a drug may be marketed. Based on a file prepared<br />
by the manufacturer that includes the data and methodology underlying the<br />
modelling of the new drug’s anticipated cost–effectiveness, the CEESP issues<br />
an opinion on the drug relative to existing therapeutic strategies, including the<br />
benefits expected or observed for patient health and quality of life. Unlike other<br />
countries, there is no fixed threshold for cost–utility or cost–effectiveness. The<br />
advice of the CEESP should be used by the CEPS in its price negotiations with<br />
the manufacturer. The first CEESP opinions were issued in early 2014, and so<br />
it is too soon to evaluate the effectiveness and appropriateness of its use.<br />
An additional element in the reduction of drug expenditure has been the<br />
governmental pressure to expand the generic drug market, starting with the<br />
authorization of generic substitution under the 1999 Social Security Finance<br />
Act. For a pharmacist to substitute a generic for the brand name drug, the drug<br />
must appear on a list of drugs for which substitution is authorized. This list<br />
does not include all off-patent medicines. For example, paracetamol is not in<br />
this list. Doliprane, the brand name for paracetamol manufactured in northern<br />
<strong>France</strong> by Sanofi-Aventis, was the fourth most reimbursed drug in <strong>France</strong> in<br />
2013, accounting for €315 million and leading to suspicion of protectionism.<br />
While the possibility of generic substitution of paracetamol has been invoked<br />
since 2002 and most recently in December 2013 by the ANSM, for the moment<br />
the government has chosen instead to reduce the price of the brand name drug<br />
(Cour des comptes, 2014b).<br />
In terms of market share, generic drugs in <strong>France</strong> represent a much lower<br />
proportion of reimbursable drugs than in other European countries. The generic<br />
market’s volume share (drug packages sold) grew from 3.4% in 1999 to 23%<br />
in 2011. However, in terms of value, it only accounted for 10.9% of the market.<br />
According to IGAS, the list of substitutable drugs in <strong>France</strong> is much more<br />
restrictive than in countries such as the Netherlands and Germany, which have